We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

236 hedge funds and large institutions have $1.83B invested in Pacific Biosciences in 2022 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 65 increasing their positions, 77 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more call options, than puts

Call options by funds: $24.6M | Put options by funds: $14.5M

49% more capital invested

Capital invested by funds: $1.23B → $1.83B (+$598M)

48% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 29

5.23% more ownership

Funds ownership: 94.23% → 99.45% (+5.2%)

4% more funds holding

Funds holding: 227 → 236 (+9)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

16% less repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 77

Holders
236
Holders Change
+9
Holders Change %
+3.96%
% of All Funds
3.79%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
43
Increased
65
Reduced
77
Closed
29
Calls
$24.6M
Puts
$14.5M
Net Calls
+$10.1M
Net Calls Change
+$18.4M

Top Buyers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$36.3M
2
FCM
Farallon Capital Management
California
+$34.5M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$24.1M
4
Ameriprise
Ameriprise
Minnesota
+$13.6M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$9.46M

Top Sellers

Rank Fund Capital Flow
1
JSP
Jackson Square Partners
California
-$45.3M
2
AIM
ARK Investment Management
Florida
-$25.9M
3
Capital International Investors
Capital International Investors
California
-$20.2M
4
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$12.9M
5
DM
Deerfield Management
New York
-$11.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
EI
226
Ellevest Inc
New York
$417 +$439 +51 New
PA
227
Parallel Advisors
California
$376 – – –
CWP
228
Concord Wealth Partners
Virginia
$188 +$198 +23 New
FFA
229
Fairfield Financial Advisors
Massachusetts
$164 – – –
FGAM
230
Financial Gravity Asset Management
Texas
$146 -$34 -4 -33%
PAG
231
Private Advisor Group
New Jersey
$105 -$7.75K -900 -7%
Federated Hermes
232
Federated Hermes
Pennsylvania
$8 – – –
HNB
233
Huntington National Bank
Ohio
$8 – – –
DM
234
Deerfield Management
New York
– -$11.7M -2,021,000 Closed
1WCM
235
12 West Capital Management
New York
– -$11.2M -1,925,000 Closed
Alyeska Investment Group
236
Alyeska Investment Group
Illinois
– -$4.06M -700,000 Closed
TI
237
Trexquant Investment
Connecticut
– -$2.63M -453,524 Closed
N
238
Natixis
France
– -$2.3M -391,993 Closed
MCM
239
Moore Capital Management
New York
– -$2.26M -389,909 Closed
SCM
240
Shelton Capital Management
Colorado
– -$1.64M -282,100 Closed
HF
241
HRT Financial
New York
– -$876K -151,070 Closed
PCM
242
Prelude Capital Management
New York
– -$516K -88,851 Closed
CAC
243
Cowen and Company
New York
– -$41K -84,400 Closed
Capital Fund Management (CFM)
244
Capital Fund Management (CFM)
France
– -$485K -83,468 Closed
CC
245
Centiva Capital
New York
– -$414K -71,191 Closed
CAM
246
Cresset Asset Management
Illinois
– -$281K -48,405 Closed
SEC
247
Seven Eight Capital
New York
– -$278K -47,806 Closed
XT
248
XTX Topco
Cayman Islands
– -$183K -31,526 Closed
Los Angeles Capital Management
249
Los Angeles Capital Management
California
– -$160K -27,526 Closed
BFS
250
Bradley Foster & Sargent
Connecticut
– -$126K -21,658 Closed
7 8 9
10
11

PACB Hedge Fund Activity: Q4 2022 in Review

236 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2022, worth a combined $1.83B — up 49% from $1.23B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new PACB positions and 29 closed out — a net gain of 14 holders — while 65 added to existing stakes and 77 trimmed.

The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $36.3M. The largest seller was Jackson Square Partners, cutting an estimated $45.3M.

  • 236 institutional investors held Pacific Biosciences (PACB) as of Q4 2022, up from 227 in Q3 2022.
  • Funds reported $1.83B of Pacific Biosciences stock for Q4 2022, up 49% quarter-over-quarter.
  • 43 funds opened new Pacific Biosciences positions in Q4 2022 and 29 closed out, a net change of +14 holders.
  • The largest Pacific Biosciences buyer in Q4 2022 was Lord, Abbett & Co, an estimated $36.3M added.
  • The largest Pacific Biosciences seller in Q4 2022 was Jackson Square Partners, an estimated $45.3M sold.

Based on aggregated 13F filings for Q4 2022.